Adjuvant Vaccination With Melanoma Antigen Pulsed Dendritic Cells (DCs) in Stage III Melanoma Patients

NCT01082198 Phase 1/Phase 2 UNKNOWN

RATIONALE: Vaccines made from dendritic cells and tumor antigen peptides or a person's tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best way to give melanoma vaccine in treating patients with stage III melanoma after surgery to remove the lymph nodes.

Details

Lead sponsor	Maria Sklodowska-Curie National Research Institute of Oncology
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	22
Start date	2002-10

Conditions

• Melanoma (Skin)

Interventions

• HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine
• HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine
• autologous melanoma lysate-pulsed autologous dendritic cell vaccine
• autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine
• dendritic cell-idiotype-keyhole limpet hemocyanin vaccine
• flow cytometry
• adjuvant therapy

Primary outcomes

• Immune response
• Disease-free survival
• Overall survival
• Adverse events

Countries

Poland